Research
Hormonal
Bariatric surgery (RYGB and VSG) is more effective than intensive medical/lifestyle therapy for the resolution of type 2 diabetes, often occurring prior to significant weight loss.
If you have Type 2 Diabetes, surgery (RYGB or VSG) is significantly more effective at resolving the disease than medication and lifestyle changes alone. Resolution can happen even before significant weight loss. Patients with shorter diabetes duration and higher pre-op C-peptide levels have the best chance of resolution.
StrongSupportsHIGH confidence
bariatric surgery (RYGB and VSG) is more effective than intensive lifestyle therapy alone for diabetes treatment and has sustained benefits, including weight loss up to 5 years
Why this rating
Supported by randomized trials STAMPEDE and DSS.
Source
Surgical treatment of obesity
Vance L. Albaugh et al. · F1000Research · 2018
DOI 10.12688/f1000research.13515.1
narrative_reviewCited 55×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Bariatric surgery significantly reduces all-cause mortality and mortality from specific chronic diseases (diabetes, CAD, cancer) compared to non-surgical management.Strong
- Bariatric surgery confers a protective effect against cancer mortality, potentially driven by weight loss and intrinsic surgical changes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →